Table 3.
Therapies, admission rates, and 3-day ED revisits
| Characteristics | n (%) N= 42909 | Median (IQR) | Per year change |
|---|---|---|---|
| Therapies | |||
| IM epinephrine | 22846 (53.2) | 55.3 (50.1, 59.9) | −0.2 (−3.8, 3.5) |
| Corticosteroids | 28125 (65.5) | 73.8 (63.9, 81.4) | −19.6 (−26.3, −12.4) |
| Antihistamines | 24527 (57.2) | 59.9 (53.5, 65.5) | −5.9 (−9.3, −2.5) |
| H2 antagonists | 21419 (49.9) | 56.8 (42.3, 66.2) | −14.3 (−20.6, −7.5) |
| Bronchodilators | 6256 (14.6) | 15.1 (12.5, 17.0) | −11.3 (−13.7, −8.9) |
| Racemic epinephrine | 640 (1.5) | 1.1 (0.6, 1.9) | −8.5 (−13.2, −3.5) |
| IV fluid bolus | 8315 (19.4) | 19.8 (11.3, 29.3) | −12.0 (−17.3, −6.4) |
| Intubation | 77 (0.2) | 0.2 (0.0, 0.3) | −4.7 (−14.3, 6.1) |
| Vasopressor | 197 (0.5) | 0.3 (0.0, 0.6) | −2.6 (−14.5, 11.0) |
| ED-disposition | |||
| Admission | 1793 (4.2) | 3.5 (2.2, 6.0) | −13.8 (−17.9, −9.5) |
| ICU admission | 716 (1.7) | 1.5 (0.8, 2.2) | −5.7 (−11.0, −0.2) |
| Fatalities | 6 (0.0) | -- | -- |
| 3-day ED revisit * | 272 (0.7) | 0.6 (0.4, 0.9) | −1.6 (−8.6, 5.9) |
*
The denominator for calculating ED revisits for anaphylaxis was 41,116 because revisits were only assessed for patients discharged from the ED during the index encounter and did not include patients hospitalized during the index encounter.